SCHEMBL22553742

SCHEMBL22553742

O=C1NCc2c(-c3cncc(-c4ccc(N5CCCC5=O)cc4)c3)ccnc21

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP11B2 P19099 4/20 0.40
NPC1 O15118 1/20 0.39
PIM1 P11309 2/20 0.38
CD38 P28907 1/20 0.37
GAA P10253 1/20 0.36
TBK1 Q9UHD2 1/20 0.36
PIP4K2A P48426 1/20 0.36
ALDH1A1 P00352 1/20 0.36
CYP11B1 P15538 3/20 0.35
CCNC P24863 2/20 0.35
CDK8 P49336 2/20 0.35
PRKAB2 O43741 1/20 0.35
PRKAG1 P54619 1/20 0.35
PRKAA2 P54646 1/20 0.35
PRKAA1 Q13131 1/20 0.35
PRKAG3 Q9UGI9 1/20 0.35
PRKAG2 Q9UGJ0 1/20 0.35
PRKAB1 Q9Y478 1/20 0.35
HPGDS O60760 1/20 0.35
IP6K1 Q92551 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30730827 1.00 CYP11B2 (0.40) CYP11B2NPC1PIM1CD38GAA
SCHEMBL22553778 0.86 TGFBR1 (0.36) CYP11B2NPC1CD38GAATBK1
SCHEMBL30730809 0.86 TGFBR1 (0.36) CYP11B2NPC1CD38GAATBK1
SCHEMBL22553771 0.82 PIP4K2A (0.40) CYP11B2NPC1PIM1CD38GAA
SCHEMBL30730847 0.82 PIP4K2A (0.40) CYP11B2NPC1PIM1CD38GAA
SCHEMBL22553750 0.79 CYP11B2 (0.39) CYP11B2NPC1PIM1CD38GAA
SCHEMBL22553788 0.78 CD38 (0.39) CYP11B2NPC1PIM1CD38GAA
SCHEMBL22553955 0.78 PIM1 (0.42) CYP11B2NPC1PIM1CD38GAA
SCHEMBL22553899 0.78 NUDT1 (0.46) NPC1CD38TBK1CDK8PRKAA1
SCHEMBL22553843 0.78 CD38 (0.39) CYP11B2NPC1PIM1CD38GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11919902-B2 Aryl-bipyridine amine derivatives as phosphatidylinositol phosphate kinase inhibitors HIBERCELL, INC. (US) 2024-03-05 US claimed
CN-112088157-A Aryl-bipyridine amine derivatives as phosphoinositide kinase inhibitors 拉文纳制药公司 2020-12-15 CN claimed
EP-3728230-A1 ARYL-BIPYRIDINE AMINE DERIVATIVES AS PHOSPHATIDYLINOSITOL PHOSPHATE KINASE INHIBITORS Ravenna Pharmaceuticals, Inc. (US) 2020-10-28 EP claimed
US-20200331913-A1 ARYL-BIPYRIDINE AMINE DERIVATIVES AS PHOSPHATIDYLINOSITOL PHOSPHATE KINASE INHIBITORS HIBERCELL, INC. 2020-10-22 US claimed
US-11919902-B2 Aryl-bipyridine amine derivatives as phosphatidylinositol phosphate kinase inhibitors HIBERCELL, INC. (US) 2024-03-05 US disclosed
CN-112088157-A Aryl-bipyridine amine derivatives as phosphoinositide kinase inhibitors 拉文纳制药公司 2020-12-15 CN disclosed
EP-3728230-A1 ARYL-BIPYRIDINE AMINE DERIVATIVES AS PHOSPHATIDYLINOSITOL PHOSPHATE KINASE INHIBITORS Ravenna Pharmaceuticals, Inc. (US) 2020-10-28 EP disclosed
US-20200331913-A1 ARYL-BIPYRIDINE AMINE DERIVATIVES AS PHOSPHATIDYLINOSITOL PHOSPHATE KINASE INHIBITORS HIBERCELL, INC. 2020-10-22 US disclosed
US-20200331913-A1 ARYL-BIPYRIDINE AMINE DERIVATIVES AS PHOSPHATIDYLINOSITOL PHOSPHATE KINASE INHIBITORS HIBERCELL, INC. 2020-10-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200331913-A1 ARYL-BIPYRIDINE AMINE DERIVATIVES AS PHOSPHATIDYLINOSITOL PHOSPHATE KINASE INHIBITORS PIP5K1A, PIP5K1B, PIP5K1C CYP11B2 3643/4885NPC1 1648/4885PIM1 669/4885
US-11919902-B2 Aryl-bipyridine amine derivatives as phosphatidylinositol phosphate kinase inhibitors PIP5K1A, PIP5K1B, PIP5K1C CYP11B2 3643/4885NPC1 1648/4885PIM1 669/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.